Slide 1: FY2024 Financial Results Presentation
FY2024 Financial Results Presentation May 15, 2025 Mochida Pharmaceutical Co., Ltd.
Slide 2: Agenda
Agenda ・FY2024 Overview ・FY2025 Forecast ・Progress on the Development FY2024 Financial Results Presentation 2
Slide 3: FY2024 Overview
FY2024 Overview FY2024 Financial Results Presentation 3
Slide 4: Summary of FY2024
Summary of FY2024 Consolidated Financial Results Increase in Net sales Increase in Operating profits Net sales increased due to Operating profit increased due to an increase in the growth of new drugs. gross profit resulting from an increase in sales in the pharmaceutical business and a decrease （
Slide 5: Consolidated operating results in FY2024
Consolidated operating results in FY2024 (Millions of yen) FY2024 Forecast FY2023 FY2024 Y o Y change (announced on May 13, 2024) (Y o Y change) (Y o Y change) (Y o Y change) 102,885 105,159 106,000 Net sales 2,273 (-0.4％) (2.2％) (3.0％) 5,802 8,126 7,500 Operating profit 2,323 (-31.8％) (40.1％) (29.3
Slide 6: Net sales by business in FY2024
Net sales by business in FY2024 (Millions of yen) FY2024 Forecast FY2023 FY2024 Y o Y change (announced on May 13, 2024) (Y o Y change) (Y o Y change) (Y o Y change) 102,885 105,159 106,000 Net sales 2,273 (-0.4％) (2.2％) (3.0％) Pharmaceuticals 96,455 97,989 99,180 1,534 business (-0.9％) (1.6％) (2.8％
Slide 7: Sales of major products in FY2024 (1/2)
Sales of major products in FY2024 (1/2) （Billions of yen） FY2024 Products FY2023 Y o Y change Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda 14.5 15.1 0.6 5% Treatment for chronic Goofice 7.7 8.3 0.6 8% constipation Treatment for chronic Movicol 5.9 6.6 0.7 12% constipation Gou
Slide 8: Sales of major products in FY2024 (2/2)
Sales of major products in FY2024 (2/2) （Billions of yen） FY2024 Products FY2023 Y o Y change Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and arteriosclerosis obliterans Epadel 7.4 4.8 -2.5 -34% Antidepressant Lexapro 5.2 2.5 -2.6 -51% Calcium channel blocker with a long-acting
Slide 9: Consolidated financial statements
Consolidated financial statements （Millions of yen） FY2023 FY2024 YoY Major fluctuation factors （Millions of yen） （As of Mar. 31, 2024） （As of Mar. 31, 2025） change Y o Y change Total assets 158,800 160,121 1,321 Cash and time deposits 11,863 Total current Accounts receivable -3,220 assets 116,662 1
Slide 10: FY2025 Forecast
FY2025 Forecast FY2024 Financial Results Presentation 10
Slide 11: Prospects for FY2025
Prospects for FY2025 Pharmaceuticals Maximizing the product value of major new drugs Expanding Omvoh and Cortiment by focusing on the gastroenterology Further growth of Goofice, Urece and Treprost etc. Further value enhancement of High Purity EPA formulation and Dienogest formulation Exp
Slide 12: Consolidated financial forecast in FY2025
Consolidated financial forecast in FY2025 (Millions of yen) FY2023 FY2024 FY2025 Forecast （Y o Y change) （Y o Y change） （Y o Y change） 102,885 105,159 110,500 Net sales (-0.4％) (2.2％) (5.1％) 5,802 8,126 7,000 Operating profit (-31.8％) (40.1％) (-13.9％) Ratio of operating 5.6％ 7.7％ 6.3％ profit to net
Slide 13: Forecast by business in FY2025
Forecast by business in FY2025 (Millions of yen) FY2023 FY2024 FY2025 Forecast (Y o Y change) (Y o Y change) (Y o Y change) 102,885 105,159 110,500 Net sales (-0.4％) (2.2％) (5.1％) Pharmaceuticals 96,455 97,989 103,000 business (-0.9％) (1.6％) (5.2％) Healthcare 6,430 7,169 7,400 business (8.6％) (11.5％
Slide 14: Forecast of major products in FY2025 (1/2)
Forecast of major products in FY2025 (1/2) （Billions of yen） FY2025 Forecast Products FY2024 Y o Y change Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda 15.1 15.1 -0.0 -0% Treatment for chronic Goofice 8.3 9.0 0.6 8% constipation Treatment for chronic Movicol 6.6 6.6 0.0 0% con
Slide 15: Forecast of major products in FY2025 (2/2)
Forecast of major products in FY2025 (2/2) （Billions of yen） FY2025 Forecast Products FY2024 Y o Y change Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and arteriosclerosis obliterans Epadel 4.8 3.6 -1.1 -24% Antidepressant Lexapro 2.5 0.7 -1.8 -71% Calcium channel blocker with a
Slide 16: Progress on the Development
Progress on the Development FY2024 Financial Results Presentation 16
Slide 17: Development Pipeline: Ethical drugs
Development Pipeline: Ethical drugs Development Stage Remarks Indications code Phase Ⅱ Phase Ⅲ Filed Approved ＜Development country＞ Pulmonary hypertension Licensed-in from United Therapeutics Corporation associated with MD-711 interstitial lung disease In-house development (additional indication) <J
Slide 18: Development Pipeline: Medical devices
Development Pipeline: Medical devices Stage Development code Intended use Remarks Therapeutic Therapeutic or product name or indications ＜Development country＞ exploratory confirmatory Filed Approved study study Peripheral nerve In-house development ReFeel injury <USA> Articular cartilage In-house de
Slide 19: FY2024 Financial Results Presentation
FY2024 Financial Results Presentation 19
Slide 20: Disclaimer (1/2)
Disclaimer (1/2) This material is an English translation of the Financial Results Presentation for the Fiscal Year 2024 to be issued on May 15, 2025 in Japanese, and the Japanese presentation is given priority regarding content and interpretation. The information provided in this material contai
Slide 21: Disclaimer (2/2)
Disclaimer (2/2) Approved products contain risks relating to manufacturing and marketing which include, but not are limited to, situations in which the Company may face deficiencies in manufacturing capacity needed to meet demand, difficulties in securing the supplies of raw materials, and demand